Cargando…
Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target
During tumor development and progression, intrinsic and extrinsic factors trigger endoplasmic reticulum (ER) stress and the unfolded protein response, resulting in the increased expression of molecular chaperones to cope with the stress and maintain tumor cell survival. Heat shock protein (HSP) GRP9...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062746/ https://www.ncbi.nlm.nih.gov/pubmed/33898309 http://dx.doi.org/10.3389/fonc.2021.629846 |
_version_ | 1783681825541980160 |
---|---|
author | Duan, Xiaofeng Iwanowycz, Stephen Ngoi, Soo Hill, Megan Zhao, Qiang Liu, Bei |
author_facet | Duan, Xiaofeng Iwanowycz, Stephen Ngoi, Soo Hill, Megan Zhao, Qiang Liu, Bei |
author_sort | Duan, Xiaofeng |
collection | PubMed |
description | During tumor development and progression, intrinsic and extrinsic factors trigger endoplasmic reticulum (ER) stress and the unfolded protein response, resulting in the increased expression of molecular chaperones to cope with the stress and maintain tumor cell survival. Heat shock protein (HSP) GRP94, also known as GP96, is an ER paralog of HSP90 and has been shown to promote survival signaling during tumor-induced stress and modulate the immune response through its multiple clients, including TLRs, integrins, LRP6, GARP, IGF, and HER2. Clinically, elevated expression of GRP94 correlates with an aggressive phenotype and poor clinical outcome in a variety of cancers. Thus, GRP94 is a potential molecular marker and therapeutic target in malignancies. In this review, we will undergo deep molecular profiling of GRP94 in tumor development and summarize the individual roles of GRP94 in common cancers, including breast cancer, colon cancer, lung cancer, liver cancer, multiple myeloma, and others. Finally, we will briefly review the therapeutic potential of selectively targeting GRP94 for the treatment of cancers. |
format | Online Article Text |
id | pubmed-8062746 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80627462021-04-24 Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target Duan, Xiaofeng Iwanowycz, Stephen Ngoi, Soo Hill, Megan Zhao, Qiang Liu, Bei Front Oncol Oncology During tumor development and progression, intrinsic and extrinsic factors trigger endoplasmic reticulum (ER) stress and the unfolded protein response, resulting in the increased expression of molecular chaperones to cope with the stress and maintain tumor cell survival. Heat shock protein (HSP) GRP94, also known as GP96, is an ER paralog of HSP90 and has been shown to promote survival signaling during tumor-induced stress and modulate the immune response through its multiple clients, including TLRs, integrins, LRP6, GARP, IGF, and HER2. Clinically, elevated expression of GRP94 correlates with an aggressive phenotype and poor clinical outcome in a variety of cancers. Thus, GRP94 is a potential molecular marker and therapeutic target in malignancies. In this review, we will undergo deep molecular profiling of GRP94 in tumor development and summarize the individual roles of GRP94 in common cancers, including breast cancer, colon cancer, lung cancer, liver cancer, multiple myeloma, and others. Finally, we will briefly review the therapeutic potential of selectively targeting GRP94 for the treatment of cancers. Frontiers Media S.A. 2021-04-09 /pmc/articles/PMC8062746/ /pubmed/33898309 http://dx.doi.org/10.3389/fonc.2021.629846 Text en Copyright © 2021 Duan, Iwanowycz, Ngoi, Hill, Zhao and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Duan, Xiaofeng Iwanowycz, Stephen Ngoi, Soo Hill, Megan Zhao, Qiang Liu, Bei Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target |
title | Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target |
title_full | Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target |
title_fullStr | Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target |
title_full_unstemmed | Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target |
title_short | Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target |
title_sort | molecular chaperone grp94/gp96 in cancers: oncogenesis and therapeutic target |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062746/ https://www.ncbi.nlm.nih.gov/pubmed/33898309 http://dx.doi.org/10.3389/fonc.2021.629846 |
work_keys_str_mv | AT duanxiaofeng molecularchaperonegrp94gp96incancersoncogenesisandtherapeutictarget AT iwanowyczstephen molecularchaperonegrp94gp96incancersoncogenesisandtherapeutictarget AT ngoisoo molecularchaperonegrp94gp96incancersoncogenesisandtherapeutictarget AT hillmegan molecularchaperonegrp94gp96incancersoncogenesisandtherapeutictarget AT zhaoqiang molecularchaperonegrp94gp96incancersoncogenesisandtherapeutictarget AT liubei molecularchaperonegrp94gp96incancersoncogenesisandtherapeutictarget |